0.1-0.3mm Spicule Skincare: Indie Founder Spec Sheet (2026)

By the ALTA MEET editorial team | K-beauty ODM consulting (NYC × Seoul)

A founder we worked with this spring sent us a six-line brief for her second SKU. The brief was one paragraph: "Spicule serum. Korean ODM. Stable. Ready for Sephora by Q1." She had a TikTok deck of three spicule products clearing 12 million views combined and a polished moodboard. What she did not have was a particle size she wanted, a sourcing tier she could afford, an INCI line she could legally print, or a safety claim that would survive a US regulator's coffee. Two months and four ODM calls later she still had not signed a sample order, because no one on her three vendor calls would commit to writing the words "0.1 to 0.3 millimeter spicule" on a quote.

That paragraph is more or less the entire reason this piece exists. Spicule skincare is the most-searched indie K-beauty active in mid-2026 and one of the few categories where founders are still negotiating in the dark. The hero ingredient looks simple on a marketing brief. It is dense the moment you have to specify what you actually want.

The point of this piece is to give an indie founder a spec sheet she can take to a Korean ODM call. We will work through what a spicule actually is (and is not), why 0.1 to 0.3 millimeter is the size band the category has converged on, how Korean ODMs source these particles, what to write on a quote so the wrong thing does not get shipped, how to formulate around the suspension and stability traps, what the FDA actually says about calling a cosmetic "microneedling," and the per-unit cost math at the MOQ tiers an indie brand can realistically run.

This sheet is built on roughly two dozen indie K-beauty spicule briefs we have read alongside founders over the past fourteen months across boutique Anyang and Hwaseong sites, mid-tier ODMs, and one tier-one quote at Cosmax. No two of those briefs converged on the same spec without intervention. That is the entire reason a written spec sheet matters.

What a spicule actually is (and what the labels are hiding)

A spicule is a needle-shaped skeletal element. The ones used in skincare come from two main biological sources, plus a small but growing thread of laboratory synthetics.

The first source is freshwater sponges of the genus Spongilla (most commonly Spongilla lacustris), harvested from lakes in China, Russia, and Eastern Europe, dried, milled, and acid-cleaned. These are the workhorse spicules of the current K-beauty wave. Their composition is dominated by amorphous silica with smaller fractions of calcium carbonate and a chitin-like organic scaffold that gets degraded during processing. The geometry under a scanning electron microscope is a needle with two tapered ends, typically 200 to 300 micrometers long and 10 to 15 micrometers in cross-section (INCIGuide entry for Spongilla lacustris spicule extract; supplier specs for Hydrolyzed Sponge by various Chinese and Korean bulk material houses).

The second source is marine sponges and other marine organisms with siliceous or calcareous spicules. These are still niche in K-beauty because the regulatory paperwork around marine biomaterial in the US and EU is fussier than freshwater sourcing.

The third source is laboratory-synthesized spicules, sometimes called "biomimetic spicules," typically extruded silica needles or calcium carbonate needles. These are not common in current K-beauty product but are starting to appear in clinical-grade serum briefs because the particle distribution is far tighter.

Across all three, the INCI label most founders will land on is one of three:

The most common is Hydrolyzed Sponge (formerly written "Hydrolyzed Sponge Spicule"), the standard INCI name for processed Spongilla skeleton. This is what most Korean ODMs will reference. The "hydrolyzed" prefix is a touch misleading because the silica itself is not hydrolyzed; the chitin matrix is enzymatically broken down so the needles release cleanly. The label tells a consumer almost nothing about particle size, which is exactly why a founder spec matters.

The second is Spongilla Lacustris Extract or Spongilla Lacustris Spicule Extract, used by some suppliers and brands to signal the species explicitly. It is the same underlying material with a different naming convention.

The third, used in laboratory-synthesized spicule products, is Silica (with grade descriptors in the safety data sheet) and sometimes Calcium Carbonate. The INCI here is generic but the geometry is what carries the function.

If a Korean ODM writes only "Hydrolyzed Sponge 99%" on a sample quote and the brief does not specify the particle distribution, the brand has agreed to whatever Spongilla lot is closest to the formulator's bench. That is the single most common upstream cost-of-quality failure we see in this category.

Why 0.1 to 0.3 millimeter is the band the category converged on

The numbers indie founders see in the press, on TikTok, and in supplier marketing decks cluster between 100 and 300 micrometers (0.1 to 0.3 millimeters). That range is not arbitrary. It is the engineering window where three constraints meet.

The first constraint is stratum corneum penetration. The outermost layer of skin is roughly 10 to 40 micrometers thick depending on body site. A spicule below 50 micrometers will mostly sit on the surface like a fine abrasive grain. A spicule between 100 and 300 micrometers can mechanically perforate the stratum corneum and seat into the upper epidermis, where it sits for hours and is exfoliated away by the natural cell turnover cycle. That is the mechanism behind the "microchannel" claim category brands lean on. Below the lower bound, the channels are too shallow to do useful work. Above the upper bound, the spicule starts engaging the upper dermis, which raises the regulatory bar from "cosmetic exfoliant" toward "device that punctures skin for aesthetic use," a distinction we will return to.

The second constraint is sensory tolerance. Spicules cause the prickling sensation famously described in product reviews. Spicules at the low end of the 100-to-300 band produce a mild warm-prickle most users can carry through a five-minute mask routine. Spicules at the upper end produce an aggressive sting that many users abandon mid-application, which becomes a returns problem. Most consumer products designed for at-home use are formulated toward the 150 to 230 micrometer middle band.

The third constraint is formulation stability. Spicules are dense, sharp, anisotropic particles. Longer spicules settle faster and cluster more aggressively in a stagnant carrier. The 100 to 300 micrometer window is the band where a properly suspended product can stay homogeneous for 18 to 24 months without resorting to a two-phase shake-before-use SKU.

When a Korean ODM samples four bench lots at 100, 150, 200, and 300 micrometers and gives you the resulting four tactile profiles, what you are doing is choosing where on the prickle-versus-channel-depth curve your product sits. The right answer depends on what category you are selling into. A leave-on serum aimed at sensitive-skin first-timers is typically 100 to 150 micrometers. A "professional-strength" home treatment mask is typically 200 to 300. A peel-off concentrate marketed as a one-shot treatment can go to 300 if the SKU is single-use and the consumer is briefed.

Write the size band on the brief. "Hydrolyzed Sponge spicules, 150 ± 30 µm median length, ≤10% above 250 µm, characterized by laser diffraction" is a real founder spec. "Spicule serum, stable, Sephora-ready" is not.

Sourcing landscape in Korea (and the four upstream suppliers behind most of what you will see quoted)There are roughly four upstream raw material houses that supply the bulk of spicule material to Korean ODMs in 2026. Naming them gets messy because the same lot of Spongilla powder will pass through two or three resellers before it lands on your ODM bench, and the resellers brand it under their own SKU names. The four substantive origin points we see most frequently on Korean Certificate of Analysis sheets are:

A China-based group of Spongilla harvesters and processors operating mostly out of Heilongjiang and Jilin, which supplies the vast majority of mid-tier indie spicule SKUs globally. Their material is the cheapest, the particle distribution is the widest, and the lot-to-lot variability is the highest. Acceptable for a first-launch indie SKU if the spec is loose and the budget is tight.

A Russia-based harvester group (Lake Baikal region historically) whose material has tighter particle distribution but inconsistent supply since 2022 sanctions complicated forward contracts.

A small handful of Korean processors. The most visible at the time of this writing is Ecotech Inc. of Incheon (the supplier behind "EC-Spicule Hydrolyzed Sponge," documented in their 2025 product brief), which markets a hydrolyzed sponge spicule line specifically positioned for K-beauty ODMs and includes characterization data that overseas suppliers rarely volunteer.

A growing set of laboratory-synthesized spicule houses, mostly biotech spinouts in Seoul and Daejeon, that produce silica needles to a much tighter distribution than the natural material can hit. The unit price is two to four times what biological Spongilla costs, but the consistency across lots is meaningfully better.

Most Korean ODMs will not tell you which of these their bench formulator is using unless asked directly, because the source switches lot-by-lot based on what the procurement office can buy at price. That is normal in the category. What is not normal is a quote that does not put the supplier name, the lot number, and the particle distribution sheet in the CoA. Demand all three at sample stage.

For practical context on how this sourcing layer interacts with vendor selection at the founder tier, the same logic we wrote up for general Korean ODM sourcing channels in Direct vs Trading House vs US Broker (2026) applies here, with one caveat: a US broker is rarely worth the markup on spicule SKUs because the raw material specification is so technical that having the formulator one phone call away matters more than the procurement convenience.

Particle-size QC: what a founder should put in writing

The mistake most indie founders make on their first spicule brief is treating particle size as a single number rather than as a distribution. A real spec has four pieces:

Median length (D50). The middle of the distribution. The number a founder typically pictures when they think "spicule size." Most indie SKUs in 2026 sit between 130 and 220 micrometers at D50.

Distribution width (D10 and D90). The 10th-percentile and 90th-percentile lengths. A narrow distribution (small gap between D10 and D90) gives a predictable sensory profile and predictable channel depth. A wide distribution gives inconsistent prickle and inconsistent efficacy. A typical Spongilla lot will show D10 around 60 to 90 micrometers and D90 around 300 to 400 micrometers, which is far wider than most founders assume.

Tail control. A specification cap on how much material can exceed a given length. "≤5% above 350 µm" is a common founder ask, because the long-tail outliers are the ones that cause occasional sharp-poke complaints in consumer reviews.

Aspect ratio. Length divided by diameter. A high aspect ratio (long, thin needle) gives a different sensory profile than a low aspect ratio (short, stout needle). Spongilla spicules average somewhere between 15:1 and 25:1; lab-synthesized spicules can be tuned tighter.

The instrument most Korean ODMs use to verify these is laser diffraction (Malvern Mastersizer-class), which produces a full distribution curve. A founder spec should request the actual particle size distribution report as part of the CoA, not just a single number. Some labs use optical or scanning electron microscopy as a confirmation cross-check; a good supplier includes a representative SEM image with the lot release. Without that paper, the brand is taking the supplier's word on the most consequential single variable in the formula.

Formulation chemistry: the suspension problem nobody warns first-time founders about

A spicule is a dense (around 2.2 g/cm³ for silica-dominated Spongilla), needle-shaped, water-insoluble particle. It does not want to stay suspended. A serum carrier that looks beautiful on the bench will separate into clear top layer and white sediment in eight hours if the rheology is wrong. The standard tools formulators reach for are:

Hydroxyethyl cellulose (HEC) or xanthan gum at 0.4 to 0.8 percent, building a soft network that holds the spicules between the polymer strands. HEC gives a glassier feel; xanthan gum gives a stringier feel that some consumer panels do not love.

Sclerotium gum as a more elegant alternative to xanthan, often blended with xanthan at half the rate. It produces a gel feel that holds particles well and rinses cleanly.

Acrylates/C10-30 Alkyl Acrylate Crosspolymer (Carbomer-class) at 0.2 to 0.6 percent, neutralized to pH 5.5 to 6.5. Builds a sturdier yield-stress carrier that resists settling under long-haul shipping shock.

The combination depends on the product format. A leave-on serum typically lands on a HEC/xanthan blend with a thixotropic profile (firm at rest, thinning under finger pressure). A wash-off mask can lean on a higher carbomer load because rinse-off forgives a heavier feel. A two-step ampoule + serum kit can split the spicule into a dry ampoule and keep the carrier separately.

The second formulation trap is pH and ionic stability. Spongilla silica is generally inert across pH 4 to 8, but the residual chitin and trace calcium carbonate can introduce a slight buffering effect that pushes a low-pH formula toward neutral over storage. Stability testing should include a 3-month accelerated panel (40°C / 75% RH per ICH Q1A R2) and a real-time 6-month panel before the brand commits to a 24-month shelf life. The acid-stable actives that pair well with spicules (niacinamide at 2 to 5%, panthenol, ceramides, hyaluronic acid fractions) are mostly fine. The pH-sensitive ones (ascorbic acid, retinaldehyde) are not, and a founder asking for "vitamin C plus spicule serum" should expect a frank conversation about whether the formulation should be a two-step kit instead.

The third trap is electrolyte sensitivity. Many polymer suspension systems collapse at high ionic load. A spicule serum loaded with high-concentration salt actives (some forms of peptide acetate, some sodium salts) can separate within weeks even though the bench-day sample looked stable. This is the failure mode we see most often when an indie founder asks the ODM to "just add" a peptide complex on top of an already-stable spicule base.

Manufacturing reality: filling, packaging, and the airless bottle question

Spicule SKUs introduce three manufacturing constraints that affect cost and lead time.

Filling line shear and orifice size. Filling needles below roughly 1.5 mm internal diameter can damage spicules in transit. Most Korean ODMs running spicule lines use 2.0 to 3.0 mm filling needles and slow the line speed to roughly 60 to 70 percent of standard cream throughput. That is a 30 to 40 percent line-time premium that shows up as a $0.05 to $0.12 per-unit fill cost adder relative to a comparable non-spicule serum at the same MOQ.Packaging selection. The two viable primary packaging formats are an airless pump bottle (most common for serum positioning) and a wide-mouth jar with spatula (most common for mask positioning). A standard dropper bottle is workable but the pipette must be wide-bore; standard pharmaceutical droppers will damage the spicules and clog. An airless pump must be specified with a piston seal compatible with abrasive particulate; the cheapest off-the-shelf airless pumps will erode their valve seats within months and create a dosage failure under warranty. Specify the pump supplier and request a six-month accelerated wear test as part of the packaging brief.

Tube-and-foil pouches are common in K-beauty for sheet-mask formats but generally do not work for spicule serums because the foil pinch points create dead zones where spicules accumulate.

Across the formats, airless 30 mL serum pumps are running roughly $0.45 to $0.95 per unit at 5,000-unit packaging MOQ in Korean supply chains in mid-2026. Wide-mouth jars with spatula are running $0.30 to $0.65. Wide-bore dropper bottles are running $0.55 to $1.10 because the wide-bore pipette is a custom tooling part.

Secondary packaging. Spicule SKUs benefit from heavier secondary cartons because the primary packaging needs more shock protection in transit than a comparable smooth-formula SKU. Add roughly $0.05 per unit to the secondary cost line.

For the broader manufacturing cost stack that sits behind these numbers, see our pillar piece on Korean skincare manufacturing cost, which walks through the cost layers at every MOQ tier and explains why the per-unit number a quote shows is rarely the per-unit number that lands at the warehouse.

I am Liz, and I run ALTA MEET from Manhattan. The single biggest mistake I see indie founders make on a spicule brief is asking for the particle distribution after the sample is approved, rather than before the sample is ordered. Once a formulator has spent two weeks building a stable carrier around a particular spicule lot, asking for a different distribution restarts the bench work and adds 5 to 8 weeks. If you want a quick gut-check on a Korean ODM spicule quote before you sign the sample order, grab 15 minutes free with Liz. I will read the spec line by line.

Safety claims: the one sentence you can say, and the three you cannot

This is the section that separates a founder who launches and a founder who gets a warning letter.

The FDA's classification of microneedling devices for aesthetic use is reasonably clear. A device "that uses one or more needles to mechanically puncture and injure skin tissue for aesthetic use" is a Class II medical device, subject to 510(k) premarket notification and the special controls in 21 CFR 878.4430 (FDA microneedling devices guidance; Federal Register classification 2018-12335; 21 CFR 878.4430). The same FDA framework is explicit that the device classification does not include devices intended for transdermal delivery of topical products such as cosmetics, drugs, or biologics, and microneedling devices are not approved for delivery of cosmetics or topical medications into the skin.

That carve-out is the legal hook spicule cosmetics have leaned on. A topical product that delivers a particulate exfoliant which incidentally creates microchannels is not, by FDA reading, a "device that mechanically punctures skin for aesthetic use." It is a cosmetic. But the legal nature of the product is determined by what the manufacturer claims it does. The brand makes the regulatory category by how it labels and markets the SKU, not by what the chemistry on the bench does.

So, in practical terms, a cosmetic spicule SKU can:

• Describe itself as a "microneedling-inspired exfoliating treatment" with care to qualify the comparison as inspiration, not equivalence

• Claim "improves the appearance of skin texture" and "smooths the look of fine lines" as standard cosmetic appearance claims

• Reference the underlying physics as "creates tiny temporary surface channels" with qualifiers like "appearance of" or "feeling of"

• Make standard hydration, brightening (cosmetic appearance), and exfoliation claims that fall within FDA's cosmetic category

What a cosmetic spicule SKU cannot do, without crossing into drug or device territory:

• Claim to treat, cure, mitigate, or prevent a skin condition (acne, eczema, melasma, scarring). Any of those words pushes the product into drug classification, requiring NDA or OTC monograph compliance.

• Claim to stimulate collagen production in a way that implies a structural change to the dermis, which is the language the FDA reads as a device or drug claim rather than a cosmetic claim.

• Claim equivalent results to a professional microneedling treatment. The FDA is explicit that microneedling devices are intended to "mechanically puncture and injure skin tissue," and any spicule cosmetic claim that asserts the same outcome borrows the device intended use.

• Describe the spicules as "delivering" actives transdermally. Both the device-classification carve-out (which excludes transdermal delivery) and the drug delivery framework (which requires NDA review for transdermal drug delivery systems) shut this language down. A spicule serum can be described as helping subsequent skincare "feel like it absorbs better" or "appear to penetrate better." It cannot claim it actually does.

Under the Modernization of Cosmetics Regulation Act of 2022 (Public Law 117-328), the brand owner is the Responsible Person for safety substantiation. A spicule SKU needs a safety substantiation file that includes the lot-by-lot particle distribution, the irritation panel results (the standard 21-subject patch panel is a defensible floor; some brands run a 50-subject extended panel for sensitivity-positioning SKUs), and a documented stability dossier. The Korean ODM will run this work for a brand-owner labeled fee in the $1,800 to $4,500 range at indie tier; the brand's regulatory consultant will then need to compile and retain the safety substantiation. None of this is exotic. Failing to do it is what attracts a warning letter when a competitor reports the brand.

For the broader US founder regulatory walk-through, see our companion piece on the FDA / MoCRA / KFDA safety verification protocol, which goes deeper on the substantiation file structure and the lines between cosmetic, OTC drug, and device classifications.

Cost and MOQ tier reality at the indie founder level

We have read roughly two dozen spicule SKU quotes from Korean ODMs over the past fourteen months. The per-unit prices below are the bench formulation cost ranges we have seen at the indie tier, normalized to a 30 mL airless serum with 1 percent spicule load at the active middle of the 100 to 300 micrometer band, in a Korean-tier-two mid-tier ODM, ex-works Korea, before regulatory or shipping costs.

At a 1,000-unit pilot MOQ (boutique Anyang or Hwaseong tier), per-unit bench cost is running $7.40 to $11.20 per 30 mL airless. The spicule itself is roughly $0.30 to $0.55 of that. Most of the cost is the small-batch line-time premium on a spicule-compatible filling line, which most boutique sites do not have natively and have to subcontract.At a 3,000-unit MOQ (mid-tier Cosmecca, CTK, or similar), per-unit bench cost drops to $4.80 to $7.10. The spicule cost stays roughly flat in raw material per unit but the line-time penalty starts amortizing.

At a 5,000-unit MOQ, per-unit bench cost is $3.95 to $5.80. This is the price tier where most indie spicule SKUs actually launch.

At a 10,000-unit MOQ, per-unit bench cost is $3.20 to $4.65. Below this point the savings curve flattens out and the marginal value of the next 5,000 units shows up mostly in better packaging unit cost.

At a 25,000-unit MOQ (tier-one Cosmax or Kolmar), per-unit bench cost can come down to $2.70 to $3.85, with packaging running independently per the supplier's standing contracts. Tier-one sites have spicule-compatible filling lines in-house, so the line-time premium nearly disappears.

The most common indie launch scenario in 2026 is a 5,000-unit first PO at $4.20 to $5.30 ex-works per unit, with a 30 mL airless pump and an English+Korean carton, packed 24 to a master, with a per-unit landed cost in the US (after duty, MOCRA filing amortization, freight, and broker fees) of roughly $5.30 to $7.10. A founder who has done the math right is then pricing the SKU at $42 to $58 retail, which is the band where the category mostly sits.

For the upstream MOQ logic, see our pillar on low-MOQ Korean skincare manufacturing at 1,000 units, which is the most-clicked page on our site and walks through the tradeoffs of running below 3,000 units on a specialty SKU.

Five common mistakes we see on first spicule briefs

These are the recurring failure modes from the indie briefs we have read over the past fourteen months. They are simple. Avoiding them is the cheapest quality-control investment a first-time founder will make.

Asking for "spicules" without specifying the size band. A request without a particle distribution lets the ODM source whatever lot is on the bench, which produces a sample the founder did not order. Always specify median, D10, D90, and a tail cap.

Treating the supplier's CoA as a particle size report. A CoA verifies microbiological and chemical limits. The particle distribution is a separate document the supplier should provide on request. Make sure it is in the sample release package.

Pairing spicules with low-pH actives in a single SKU. Ascorbic acid, retinaldehyde, and most AHA blends do not coexist gracefully with spicule chemistry across a 24-month shelf life. The technically correct architecture is a two-step kit. The marketing-easy architecture is one SKU. The two-step kit costs roughly $1.20 more per unit but launches with a clean stability dossier.

Ordering an off-the-shelf airless pump without specifying the seal material. A standard pump will erode under spicule abrasion within months. Insist on a piston-and-seal material specification compatible with abrasive particulate, and request a six-month accelerated wear test from the packaging vendor.

Writing "microneedling" claims into the launch copy without a regulatory pass. This is the single fastest way to attract a competitor-reported FDA warning letter. Have a regulatory consultant red-line the launch copy before any media goes live. The cost of the legal review is roughly $1,200 to $3,500 and saves the cost of pulling and relabeling inventory.

Founder FAQ

Q: Can I get a spicule SKU made in Korea below 1,000 units? A: Technically yes through some boutique sites, but the per-unit cost makes it more expensive than buying competitor product retail for analysis. Below 1,000 units, the line-time penalty on a spicule-compatible filling line is uneconomic. Most indie founders should plan a 1,500 to 3,000 unit pilot if budget is the constraint.

Q: How do I verify the particle size on a sample without sending it to a third-party lab? A: Optical microscopy with a calibrated stage micrometer will give you a rough check (D50 and obvious tail outliers) at home for under $300 in equipment. For a publishable distribution, send a sample to a Korean third-party lab; laser diffraction runs are typically $200 to $450 per sample with a 7-to-10-day turnaround.

Q: Will a spicule SKU pass EU CPNP notification? A: Yes, with the standard CPSR Part A+B safety dossier and Responsible Person filing. The EU 1223/2009 framework treats Spongilla-derived spicules as standard cosmetic ingredients. No additional notification triggers beyond the standard cosmetic dossier.

Q: Are there country-of-origin restrictions on Spongilla material? A: The bulk of Spongilla harvesting is in China and historically Russia. Russian-origin material has had supply continuity issues since 2022. For US-bound product, ensure the supplier provides a country-of-origin declaration; some founders have run into HTS classification questions at US Customs when the country of origin was unclear.

Q: Should I specify lab-synthesized spicules over natural Spongilla? A: The tradeoff is consistency versus cost. Lab-synthesized spicules give a tighter distribution and cleaner CoA but cost two to four times more per kilogram. For a sensitive-skin SKU or a clinical-positioning brand, the premium can be worth it. For a mass-market indie SKU, Spongilla is the rational choice.

Q: How long is a typical spicule SKU launch from brief to first shipment? A: From signed brief to first 5,000-unit shipment, plan 22 to 28 weeks on a normal Korean ODM cadence. Particle-size sample iteration adds 2 to 4 weeks beyond a standard serum timeline. See our Korean ODM launch timeline guide for the gotchas that push 6 months to 9 on a complex SKU.

Q: What's the best position to take on safety claims while we are still building the brand? A: Lean on appearance language. "Skin feels smoother." "Looks more refined." "Inspired by microneedling." Keep "treats," "stimulates," "delivers," and equivalence-to-professional-treatment language out of every channel until your regulatory consultant has cleared it.

Key takeaways for an indie founder going into a Korean spicule brief

A spicule SKU is one of the highest-leverage launches an indie K-beauty brand can ship in 2026 if the brief is specified at the level a Korean ODM will respect. The leverage is the marketing story (microneedling-in-a-bottle reads cleanly in 60 seconds on social) and the manufacturing reality (Korean ODMs can run the SKU at indie MOQ without exotic equipment if the spec is right). The risk is the marketing-to-regulatory gap: the same one-sentence story that sells the SKU is the one-sentence story that attracts a warning letter if the brand says it wrong.

The founder spec sheet that survives a Korean ODM call is short. Particle size as a distribution, not a single number. INCI line written explicitly. Supplier name on the CoA. Particle distribution report attached at sample release. Pump specification with seal material and wear test. Stability dossier with both accelerated and real-time panels. Claim language reviewed by a US regulatory consultant before any media spend.

Get those eight items in writing on the quote and the SKU has a defensible path to shelf. Skip them and the launch becomes one of the case studies we read alongside founders on a fix call six months later.

Working With ALTA MEET

ALTA MEET is a New York-based Korean ODM consulting partner for indie K-beauty founders, run by Liz Song from Manhattan with Seoul-side oversight on every brief. We read sample quotes, attend ODM calls in Korean, review regulatory dossiers, and surface the questions a founder did not know to ask before signing.

If you are working on a spicule SKU and want a second pair of eyes on the particle distribution spec, the safety claim language, or the per-unit cost stack before you commit, book your free 15-min K-Beauty manufacturing gut-check with Liz.

Reviewed for accuracy by ALTA MEET's formulation consulting team.

References: FDA Microneedling Devices guidance (2026 operational); Federal Register Final Rule 2018-12335 classification of microneedling devices for aesthetic use; 21 CFR 878.4430 special controls; Modernization of Cosmetics Regulation Act of 2022 (Public Law 117-328); ICH Q1A(R2) stability testing guidelines; ISO 11930:2019 preservative challenge protocol; ISO 17516:2014 microbial limits for cosmetics; INCIGuide entry for Spongilla lacustris spicule extract; Ecotech Inc. 2025 EC-Spicule Hydrolyzed Sponge product brief; Cosmetics Business reporting on K-beauty spicule category trajectory.